2023
July 31, 2023
Neurona Therapeutics Appoints James Stutz as Chief Financial Officer and Chief Business Officer
June 15, 2023
Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epilepsy
April 24, 2023
Neurona Therapeutics Presents Updated Data from the NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2023 Annual Meeting
March 8, 2023
Neurona Therapeutics Announces Presentation at the Oppenheimer 33rd Annual Healthcare Conference
February 14, 2023
Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy
2022
December 5, 2022
Neurona Therapeutics Presents Clinical Data for NRTX-1001 Regenerative Cell Therapy for Drug-Resistant Focal Epilepsy at American Epilepsy Society Annual Meeting
November 21, 2022
Neurona Therapeutics Presents Encouraging Clinical Data from First-Ever Regenerative Human Cell Therapy Trial in Adults with Drug-Resistant Focal Epilepsy and Shows Supporting Manufacturing, Delivery, and Preclinical Data
September 21, 2022
Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy
June 29, 2022
Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy
June 17, 2022
Neurona Therapeutics to Present Preclinical Data Supporting Regenerative Cell Therapy, NRTX-1001, in Clinical Development for Chronic Focal Epilepsy, at the ISSCR 2022 Annual Meeting
May 26, 2022
Neurona Therapeutics Awarded $8 Million by California Institute for Regenerative Medicine (CIRM) to Support Phase 1/2 Clinical Trial of NRTX-1001 for Chronic Focal Epilepsy
April 4, 2022
Neurona Therapeutics to Present at the Locust Walk Stem Cell Tx Conference
April 1, 2022
Neurona Therapeutics Presents Preclinical Data at the American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001, Being Evaluated in a Phase 1/2 Clinical Trial for Chronic Focal Epilepsy
January 5, 2022
Neurona Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
2021
December 13, 2021
Neurona Therapeutics Announces C-Suite Leadership Team
December 3, 2021
Neurona Therapeutics to Present New Preclinical Data and Clinical Trial Plans for Lead Neural Cell Therapy Program, NRTX-1001, at the Annual Meeting of the American Epilepsy Society
November 18, 2021
Neurona Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference
November 8, 2021
Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Candidate NRTX-1001 at Neuroscience 2021.
November 4, 2021
Neurona Therapeutics Receives IND Clearance to Initiate Phase 1/2 Clinical Trial of Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients.
October 20, 2021
Neurona Therapeutics Appoints Brad Margus to its Board of Directors
June 22, 2021
Neurona Therapeutics Raises $41.5M to Advance Neural Network-Rebalancing Cell Therapies for the Treatment of Epilepsy and other Neurological Disorders
June 16, 2021
Neurona Therapeutics Presents Clinical Development Plan for Lead Cell Therapy Program at the 16th Conference on Antiepileptic Drug and Device Trials (AEDD TRIALS XVI
April 19, 2021
Neurona Therapeutics Presents Preclinical Data from Lead Inhibitory Cell Therapy Program, Demonstrating Significant Seizure Suppression in Model of Focal Epilepsy
2019-2015
October 31, 2019
Neurona Therapeutics awarded a $4.8M translational grant from CIRM to advance epilepsy program to the pre-IND stage
December 14, 2017
CIRM Discovery Quest Award program: Neurona Therapeutics receives funding
December 1, 2015
Neurona Therapeutics Launches with $23.5 Million in Series A Funding to Repair Damaged Neural Circuits
NRTX-1001 is an investigational candidate and is being evaluated in ongoing clinical trials. NRTX-1001 has not been approved by any regulatory authority for commercial use or deemed to be safe or effective for any indication.
